• Mutational Drivers and Drug Resistance in Myeloma Cells

  2026-08-20

  Vikova et al. established a broad exome-based map of mutations across human multiple myeloma cell lines, identifying both established drivers and previously underappreciated genes linked to oncogenic pathways and drug response. The study provides a practical framework for selecting genetically appropriate models in multiple myeloma and hematological malignancy research while clarifying the limits of cell-line-based conclusions.

• Imatinib Hydrochloride: A Phosphatase-Aware View

  2026-08-20

  Imatinib hydrochloride is a versatile ATP-site kinase probe for chronic myelogenous leukemia and gastrointestinal stromal tumor research. This article adds a phosphatase-aware framework for separating direct kinase inhibition, activation-loop regulation, and cellular phenotype.

• Epacadostat: From IDO1 Potency to Immune Context

  2026-08-19

  Epacadostat (INCB024360) is an oral IDO1 inhibitor that connects precise enzyme inhibition with complex immune-metabolic assay design. This guide explains how to interpret its potency across recombinant, cellular, and whole-blood systems without overextending the evidence.

• Thermal-Protective Hydrogel for Curative Tumor Ablation

  2026-08-19

  The reference study introduces an injectable MR@CaP@HA hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. By protecting adjacent tissue while promoting immunogenic cell death, dendritic-cell maturation, and M1 macrophage polarization, the platform improved residual-tumor control and achieved complete tumor eradication in a subset of treated animals.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-18

  The referenced preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. This structural mechanism suggests a route toward more selective p38 MAPK signaling pathway modulation, while requiring further cellular validation.

• Nerve-Mediated HDAC Control of Axolotl Regeneration

  2026-08-18

  Wang and colleagues showed that nerve input regulates a biphasic increase in HDAC1 expression during axolotl limb regeneration, particularly in the wound epidermis. Pharmacological inhibition, denervation, and growth-factor rescue experiments place HDAC1 activity upstream of blastema formation, while also defining important limits for translating these findings to cancer and other models.

• Pioglitazone PPARγ Agonist Workflows

  2026-08-17

  Pioglitazone provides a receptor-focused way to connect metabolic signaling with macrophage polarization, barrier integrity, and neuroinflammatory readouts. This guide translates PPARγ activation into practical cell, DSS-induced intestinal inflammation, beta-cell, and Parkinson’s disease model workflows, with handling and troubleshooting guidance.

• Radicicol: From Hsp90 Mechanism to Translation

  2026-08-17

  Radicicol is more than a conventional Hsp90 inhibitor: its differentiated ATPase and kinase activity profile creates a useful framework for studying proteostasis, adipogenesis, apoptosis, and inflammation. This thought-leadership analysis translates those mechanisms into assay strategy while defining the limits of preclinical interpretation.

• Cyclic di-GMP: From Biofilm Persistence to STING

  2026-08-16

  Cyclic di-GMP is more than a bacterial signaling metabolite: recent work positions this intracellular second messenger as a small-molecule antitoxin that links early biofilm development to genome instability and antibiotic persistence. This article translates that mechanistic insight into a practical framework for biofilm formation regulation, STING-focused immune modulation research, and cancer immunotherapy studies.

• Apicidin Disrupts Oocyte Maturation and Quality

  2026-08-15

  A 2026 study identifies a reproductive-toxicity mechanism for Apicidin by linking impaired oocyte maturation with spindle and actin disruption, altered histone and tubulin acetylation, DNA damage, and early apoptosis. The findings expand evaluation of this histone deacetylase inhibitor beyond somatic-cell toxicity and provide a framework for studying mycotoxin effects on germ-cell quality.

• Masitinib (AB1010) Protocol & QC Guide

  2026-08-14

  Masitinib (AB1010) is a DMSO-soluble, phenylaminothiazole-type tyrosine kinase inhibitor for targeted KIT and PDGFR research. It is suitable for cancer, mastocytosis, and inflammatory disease assays, but not for workflows requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or direct clinical dosing guidance.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-14

  Learn how to use Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor in endothelial migration, tube formation, receptor-phosphorylation, and translational cancer research workflows. This practical guide connects concentration-response data with the reference case report while emphasizing assay controls, reproducibility, and troubleshooting.

• Dinaciclib: CDK Control at Tissue Boundaries

  2026-08-13

  Discover how Dinaciclib (SCH727965) connects CDK inhibition with cell-cycle control, apoptosis, and tissue-boundary mechanics. This article translates developmental biophysics into more discriminating cancer research assays.

• Inducing Mammalian Embryonic Dormancy via mTOR

  2026-08-13

  This Nature Protocols study converts pharmacological mTOR inhibition into a reproducible in vitro method for inducing a reversible, diapause-like dormant state in mouse blastocysts, human blastoids, and pluripotent stem cells. The framework replaces invasive surgery-based approaches with scalable culture workflows and defines experimental readouts for distinguishing stable developmental dormancy from nonspecific stress or loss of viability.

• Monomethyl auristatin E in Precision Assays

  2026-08-12

  Monomethyl auristatin E (MMAE) gives researchers a potent, controllable antimitotic benchmark for cytotoxicity assays and antibody-drug conjugate development. This workflow-focused guide shows how to handle the compound, separate free-payload effects from targeting biology, and use the EBV–NPC plasticity study to design more informative combination experiments.

16614 records 1/1108 page Next 12345 下5页 Last page